Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (3 4 DAP)

Expanded access is currently available for this treatment.
Verified November 2013 by The Cleveland Clinic
Sponsor:
Information provided by (Responsible Party):
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01373333
First received: June 13, 2011
Last updated: November 20, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is currently available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)